Anixa Biosciences News

Express News | Anixa Biosciences Welcomes Celebrity Oncologist DR. Sanjay Juneja to Its Cancer Business Advisory Board

Moomoo 24/7Apr 18 08:20 ET

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to Its Cancer Business Advisory Board

Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations.

PRNewswireApr 18 08:20 ET

Anixa Biosciences(ANIX.US) Director Buys US$49,229.52 in Common Stock

$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 15,009 shares of common stock on Apr 9, 2024 at an average price of $3.28 for a total value of $49,229.52.Source: Announcement What

moomoo NewsApr 10 10:25 ET

Anixa Biosciences Stockholders Affirm Confidence and Oversight

TipRanksMar 22 16:42 ET

Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth

InvestorBrandMediaMar 21 19:20 ET

Anixa Biosciences: A Buy Rating on Strong Financials and Promising Oncology Advances

TipRanksMar 21 06:17 ET

Anixa Biosciences(ANIX.US) Director Buys US$36,300 in Common Stocks

$Anixa Biosciences(ANIX.US)$ Director Baskies Arnold M purchased 10,000 shares of Common Stocks on Mar 15, 2024 at an average price of $3.63 for a total value of $36,300.Source: Announcement What is s

moomoo NewsMar 15 14:55 ET

Anixa Biosciences(ANIX.US) Officer Buys US$96,600 in Common Stocks

$Anixa Biosciences(ANIX.US)$ Officer KUMAR AMIT purchased 30,000 shares of Common Stocks on Mar 15, 2024 at an average price of $3.22 for a total value of $96,600.Source: Announcement What is statemen

moomoo NewsMar 15 11:29 ET

Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

SAN JOSE, Calif., March 14, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of c

PR NewswireMar 14 08:45 ET

Recap: Anixa Biosciences Q1 Earnings

Anixa Biosciences (NASDAQ:ANIX) reported its Q1 earnings results on Tuesday, March 12, 2024 at 05:00 PM.Here's what investors need to know about the announcement.EarningsAnixa Biosciences missed estim

BenzingaMar 12 17:45 ET

Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress

PRNewswireMar 11 08:00 ET

Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)

TipRanksFeb 13 12:20 ET

Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment

Anixa Biosciences (ANIX) said Monday it started treatment of the fourth patient in its phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. The fourth patie

MT NewswiresFeb 12 15:45 ET

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...

PR NewswireFeb 12 07:30 ET

Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology

Anixa Biosciences (ANIX) said Tuesday that partner Cleveland Clinic has been granted a patent for its ovarian cancer vaccine technology in Japan. Anixa said it has an exclusive worldwide license for t

MT NewswiresJan 23 14:10 ET

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...

PR NewswireJan 23 07:55 ET

Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024

SAN JOSE, Calif., Jan. 10, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca

PR NewswireJan 10 09:00 ET

Anixa Biosciences to Present at Biotech Showcase 2024

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...

PR NewswireDec 14, 2023 07:15 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersDare Bioscience (NASDAQ:DARE) shares rose 31.1% to $0.46 during Thursday's pre-market session. The company's market cap stands at $44.8 million. Anixa Biosciences (NASDAQ:ANIX) shares moved upw

BenzingaDec 7, 2023 08:07 ET

Anixa Biosciences Unveils 'Positive' Results From Phase 1 Trial of Breast Cancer Vaccine

Anixa Biosciences (ANIX) unveiled late Wednesday new and updated "positive" results from its phase 1 clinical trial of the alpha-lactalbumin vaccine targeting triple-negative breast cancer. Data from

MT NewswiresDec 7, 2023 06:05 ET